Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detour ahead: possible causes of corticospinal tract truncation in upper motor neuron-predominant amyotrophic lateral sclerosis.

Brain communications·2025
Same author

Modeling ALS with Patient-Derived iPSCs: Recent Advances and Future Potentials.

Brain sciences·2025
Same author

Graph theory network analysis reveals widespread white matter damage in brains of patients with classic ALS.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2024
Same author

Intrathecal methotrexate, central nervous system toxicity, and response to N-methyl-D-aspartate antagonism: An adult case series.

Neuro-oncology practice·2024
Same author

Nanoplastics and Neurodegeneration in ALS.

Brain sciences·2024
Same author

Describing and characterising variability in ALS disease progression.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2023

Related Experiment Video

Updated: Jun 17, 2026

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.1K

Neurophysiologic Innovations in ALS: Enhancing Diagnosis, Monitoring, and Treatment Evaluation.

Ryan Donaghy1, Erik P Pioro2

  • 1Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.

Brain Sciences
|January 8, 2025
PubMed
Summary

Biomarkers are crucial for amyotrophic lateral sclerosis (ALS) research. Objective electrophysiological tools can advance diagnosis, track progression, and assess treatment efficacy in ALS clinical trials.

Keywords:
amyotrophic lateral sclerosis (ALS)biomarkerclinical trialmotor unit number estimation (MUNE)transcranial magnetic stimulation

More Related Videos

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

3.7K
Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
06:34

Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model

Published on: June 2, 2023

1.1K

Related Experiment Videos

Last Updated: Jun 17, 2026

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.1K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

3.7K
Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model
06:34

Author Spotlight: Stimulation-Based Approach to Improve Cerebral Blood Flow in Alzheimer's Model

Published on: June 2, 2023

1.1K

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Biomarker Research

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting upper motor neurons (UMNs) and lower motor neurons (LMNs), leading to motor function decline.
  • Current diagnosis relies on clinical examination and ordinal scales, but objective biomarkers are lacking for classification and progression monitoring.
  • This deficiency hinders clinical trial enrollment, complicates inclusion criteria, and impedes accurate assessment of therapeutic efficacy.

Purpose of the Study:

  • To explore the potential of electrophysiological and neuroimaging techniques as objective biomarkers in ALS.
  • To highlight how these tools can improve disease classification, predict progression, and evaluate drug efficacy in clinical trials.

Main Methods:

  • Established electrophysiology tools: nerve conduction studies (NCS) and electromyography (EMG) for LMN degeneration.
  • Advanced techniques: motor unit number estimation (MUNE), electrical impedance myography (EIM), and single-fiber EMG (sfEMG) for motor manifestations.
  • Neuroimaging and brain activity assessment: transcranial magnetic stimulation (TMS), high-density electroencephalography (hd-EEG), and magnetoencephalography (MEG) for UMN and non-motor dysfunction.

Main Results:

  • Electrophysiology tools like NCS and EMG are validated biomarkers for LMN degeneration in ALS.
  • Techniques such as MUNE, EIM, and sfEMG provide further insights into motor unit integrity and function.
  • TMS, hd-EEG, and MEG are increasingly used to assess UMN and non-motor brain area dysfunction in ALS.
  • Characterization of autonomic and sensory nervous system dysfunction in ALS is also possible.

Conclusions:

  • Electrophysiological and neuroimaging techniques offer objective, noninvasive methods for ALS research.
  • These biomarkers have the potential to identify disease subtypes and predict progression rates.
  • They can significantly aid in assessing the physiologic engagement of experimental therapies in ALS clinical trials, potentially complementing or replacing traditional outcome measures.